Claybrook Capital’s AbbVie ABBV Stock Holding History

Claybrook Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,817	Closed	-$244K	–	134
2022 Q3	$244K	Hold	1,817	–	–	0.15%	114
2022 Q2	$278K	Hold	1,817	–	–	0.16%	110
2022 Q1	$295K	Hold	1,817	–	–	0.15%	111
2021 Q4	$246K	Buy	+1,817	New	+$215K	0.12%	125
2021 Q3	–	Sell	-11,601	Closed	-$1.31M	–	126
2021 Q2	$1.31M	Buy	+11,601	New	+$1.31M	0.43%	68
2019 Q1	–	Sell	-62,003	Closed	-$5.72M	–	93
2018 Q4	$5.72M	Buy	62,003 +60,403	+3,775%	+$5.31M	1.6%	12
2018 Q3	$151K	Hold	1,600	–	–	0.09%	82
2018 Q2	$148K	Hold	1,600	–	–	0.09%	81
2018 Q1	$151K	Buy	1,600 +400	+33%	+$43.9K	0.1%	79
2017 Q4	$116K	Buy	+1,200	New	+$113K	0.08%	93

Other funds holding ABBV

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Claybrook Capital's ABBV Position: Q4 2022 in Review

Claybrook Capital sold out of AbbVie (ABBV) in Q4 2022, closing a stake of 1,817 shares — an estimated $244K sold.

Claybrook Capital first reported a position in ABBV in Q4 2017 and held it in 10 quarters. The position peaked at $5.72M in Q4 2018. 3,168 funds tracked by Wall St. Rank hold ABBV as of Q4 2022.

Claybrook Capital reported no remaining AbbVie position as of Q4 2022 after selling out during the quarter.
Claybrook Capital sold 1,817 AbbVie shares in Q4 2022, an estimated $244K.
Claybrook Capital first reported a position in AbbVie in Q4 2017 and held it in 10 quarters.
Claybrook Capital's AbbVie position peaked at $5.72M in Q4 2018.
3,168 funds tracked by Wall St. Rank held AbbVie as of Q4 2022.

Based on Claybrook Capital's 13F filing for Q4 2022, filed 24 Jan 2023.